High throughput NAPPA-proteoimmunomics and V. cholerae vaccine development

Project: Research project

Project Details

Description

Arizona State University would enter into a four year sub-contractual agreement with the Massachusetts General Hospital. Dr. Joshua LaBaer would be the site PI at ASU in the collaborative study entitled, High throughput NAPPA-proteoimmunomics & Vibrio cholerae vaccine development, MGH PI, Ryan ET. The purpose of the project is to use high throughput proteomic technology to assess immune responses to cholera and screen household contacts of cholera patients, stratifying immuno-reactivity with level of protection from cholera, as well as characterizing the proteo-immunome response following vaccination against cholera, comparing immuno-reactivity to household contacts of cholera patients. As part of this project, HIP would provide to the MGH QCverified V. cholerae NAPPA microarray chips (detailed below; DNA printed, but not expressed), sequenced verified clones of V. cholerae ORFs identified by NAPPA screening (master Gateway clones, and fusion clones), purified proteins as required, and would assist with maximizing expression and reading reproducibility and data analysis. The subcontract would correspond to years 2-5 of the project period.
StatusFinished
Effective start/end date6/1/095/31/10

Funding

  • HHS-NIH: National Institute on Alcohol Abuse & Alcoholism (NIAA): $255,924.00

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.